Freshpaint vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 39)
Freshpaint logo

Freshpaint

EmergingHealthcare

General

HIPAA-compliant analytics infrastructure for healthcare; strips PHI from tracking events before reaching Google Analytics, Meta, or other marketing tools.

AI VisibilityBeta
Overall Score
D39
Category Rank
#425 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
44
Gemini
35

About

Freshpaint is a healthcare data privacy and analytics infrastructure platform that enables digital health companies and hospitals to run marketing analytics and tracking without violating HIPAA. Founded in 2019 and headquartered in San Francisco, Freshpaint solves a critical compliance challenge: standard web analytics tools (Google Analytics, Meta Pixel, Mixpanel) capture Protected Health Information (PHI) when embedded on healthcare websites, creating HIPAA liability. Freshpaint intercepts and sanitizes tracking events before they reach third-party analytics vendors.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#425
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
44
Perplexity
93
35
Gemini
89
40
Claude
96
43
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.